Stem cell study for frailty in older adults
This study tests whether an experimental stem cell treatment called MiraMSC can help older adults with mild to moderate frailty. It aims to see if the treatment is safe and possibly improves energy or daily function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 60 and 85 years old.
- You have mild to moderate frailty (a doctor will use the Clinical Frailty Scale to confirm).
- You weigh between 88 and 198 pounds (40 to 90 kg).
- You are not currently using strong immune-suppressing medications.
- You have not had another stem cell treatment in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental stem cell product called StromaForte for people with aging frailty. It involves a single infusion of cells from a donor to see if it can improve strength and walking ability.
This early study (Phase 1) tests whether a lab-made stem cell product given through an IV is safe in people with “aging frailty.” It looks mainly at side effects and safety while also exploring whether the treatment can be given safely.
This trial tests whether a Spanish health-clinic–guided exercise program can improve frailty in people who are starting to become frail (“pre-frail”). It may help you build strength and walking ability through supervised physical activity.
This study tests whether a lifestyle intervention can help prevent frailty and age-related health problems. If you are between 60 and 90 years old, have some signs of frailty, and can use a mobile app with help, you may be able to join.
This study tests whether a specially designed exercise program can help older adults who are frail or losing muscle strength feel stronger and more independent. The program is run by physical therapists at your usual health center.
This trial tests a personalized treatment approach for people aged 65 and older with newly diagnosed multiple myeloma. The goal is to tailor therapy based on each patient's level of frailty, which could help improve outcomes and reduce side effects.
Hear when a new Frailty trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.